Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663491 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL5169810 | 0.82 | SLC6A4 (0.46) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL4663657 | 0.82 | TRPA1 (0.36) | OPRK1OPRM1OPRD1MEN1KMT2A | |
| SCHEMBL4664145 | 0.82 | OPRK1 (0.58) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL4663665 | 0.82 | ALDH1A1 (0.36) | OPRK1OPRM1OPRD1 | |
| SCHEMBL4663539 | 0.80 | SLC6A4 (0.47) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL4665394 | 0.79 | OPRK1 (0.65) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL4663603 | 0.79 | SLC6A4 (0.46) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL8022895 | 0.78 | OPRK1 (0.64) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 | |
| SCHEMBL4663468 | 0.78 | SLC6A4 (0.53) | SLC6A4SLC6A2OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | claimed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | claimed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | claimed |
| EP-1368299-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2002030870-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | claimed |
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| EP-1368299-B1 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1571140-A1 | C-substituted cyclohexylmethylamine derivatives | Grünenthal GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1368299-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002030870-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | CNR2, CNR1, HNMT | SLC6A4 358/4885SLC6A2 611/4885OPRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.